JP2023522193A5 - - Google Patents

Info

Publication number
JP2023522193A5
JP2023522193A5 JP2022562752A JP2022562752A JP2023522193A5 JP 2023522193 A5 JP2023522193 A5 JP 2023522193A5 JP 2022562752 A JP2022562752 A JP 2022562752A JP 2022562752 A JP2022562752 A JP 2022562752A JP 2023522193 A5 JP2023522193 A5 JP 2023522193A5
Authority
JP
Japan
Prior art keywords
seq
antigen
cells
pool
immunogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022562752A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023522193A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2021/050940 external-priority patent/WO2021209775A1/en
Publication of JP2023522193A publication Critical patent/JP2023522193A/ja
Publication of JP2023522193A5 publication Critical patent/JP2023522193A5/ja
Priority to JP2026050544A priority Critical patent/JP2026122961A/ja
Pending legal-status Critical Current

Links

JP2022562752A 2020-04-17 2021-04-19 抗原プール Pending JP2023522193A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026050544A JP2026122961A (ja) 2020-04-17 2026-03-25 抗原プール

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20170255 2020-04-17
EP20170255.2 2020-04-17
PCT/GB2021/050940 WO2021209775A1 (en) 2020-04-17 2021-04-19 Antigen pool

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026050544A Division JP2026122961A (ja) 2020-04-17 2026-03-25 抗原プール

Publications (2)

Publication Number Publication Date
JP2023522193A JP2023522193A (ja) 2023-05-29
JP2023522193A5 true JP2023522193A5 (cg-RX-API-DMAC7.html) 2024-05-20

Family

ID=70333816

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022562752A Pending JP2023522193A (ja) 2020-04-17 2021-04-19 抗原プール
JP2026050544A Pending JP2026122961A (ja) 2020-04-17 2026-03-25 抗原プール

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026050544A Pending JP2026122961A (ja) 2020-04-17 2026-03-25 抗原プール

Country Status (6)

Country Link
US (1) US20230302109A1 (cg-RX-API-DMAC7.html)
EP (1) EP4136096A1 (cg-RX-API-DMAC7.html)
JP (2) JP2023522193A (cg-RX-API-DMAC7.html)
CN (1) CN115667288A (cg-RX-API-DMAC7.html)
CA (1) CA3176754A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021209775A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3994156A1 (en) 2019-07-05 2022-05-11 The Francis Crick Institute Limited Novel cancer antigens and methods
WO2025202937A1 (en) 2024-03-26 2025-10-02 BioNTech SE Cancer vaccines

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0871747A1 (en) 1996-01-02 1998-10-21 Chiron Viagene, Inc. Immunostimulation mediated by gene-modified dendritic cells
US6770456B1 (en) 1998-07-29 2004-08-03 Ludwig Institute For Cancer Research Endogenous retrovirus tumor associated nucleic acids and antigens
EP1586330A1 (en) 2004-04-16 2005-10-19 Georg-August-Universität Göttingen Vaccination against malignant melanoma
EP2402447A1 (en) 2005-03-30 2012-01-04 Viroxis Endogenous retrovirus and proteins encoded by env gene as a target for cancer treatment
AT502292B1 (de) 2005-05-11 2010-04-15 Avir Green Hills Biotechnology Melanomdiagnose
WO2007109583A2 (en) 2006-03-17 2007-09-27 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for prevention or treatment of neoplastic disease in a mammalian subject
US20080019979A1 (en) 2006-05-22 2008-01-24 Feng Wang-Johanning HERV-K Antigens, Antibodies, and Methods
CA3052255A1 (en) * 2017-02-01 2018-08-09 Modernatx, Inc. Rna cancer vaccines
CN119978090A (zh) * 2018-10-19 2025-05-13 弗朗西斯·克里克研究所有限公司 新的癌抗原和方法
WO2020260897A1 (en) * 2019-06-28 2020-12-30 The Francis Crick Institute Limited Novel cancer antigens and methods
MX2022000263A (es) * 2019-07-05 2022-02-03 The Francis Crick Institute Ltd Nuevos antigenos y metodos contra el cancer.
EP4136097A1 (en) * 2020-04-17 2023-02-22 The Francis Crick Institute Limited Fusion proteins of ctl antigens for treating melanoma

Similar Documents

Publication Publication Date Title
JP7509504B2 (ja) 免疫療法のためのコア/シェル構造プラットホーム
Zhang et al. Two-dimensional layered double hydroxide nanoadjuvant: recent progress and future direction
US11338027B2 (en) Fusion comprising a cell penetrating peptide, a multi epitope and a TLR peptide agonist for treatment of cancer
JP6306593B2 (ja) 細胞透過性ペプチド
Sheng et al. Cancer immunotherapy and nanomedicine
JP2018509936A (ja) 結腸直腸癌を治療するための細胞透過性ペプチド、カーゴ、及びtlrペプチドアゴニストを含む新規複合体
Grippin et al. Nanotechnology for immuno-oncology
CN110124018A (zh) 一种模拟坏死肿瘤细胞的磷酸钙-脂质纳米疫苗及其应用
JP2022539157A5 (cg-RX-API-DMAC7.html)
Zeng et al. Carrier-free nanovaccine: an innovative strategy for ultrahigh melanoma neoantigen loading
JP2022514116A5 (cg-RX-API-DMAC7.html)
JP2022539585A5 (cg-RX-API-DMAC7.html)
JP2023522198A5 (cg-RX-API-DMAC7.html)
Gong et al. Tumor Microenvironment‐Activated Hydrogel Platform with Programmed Release Property Evokes a Cascade‐Amplified Immune Response against Tumor Growth, Metastasis and Recurrence
JP2022540396A5 (cg-RX-API-DMAC7.html)
Wang et al. A dissolvable microneedle platform for the delivery of tumor-derived total RNA nanovaccines for enhanced tumor immunotherapy
Guo et al. STING agonist-primed supramolecular oncolytic hydrogel vaccine for tuning tumors against themselves
Chen et al. Nanovehicles for delivery of antigens and adjuvants as cancer nanovaccines
Huang et al. Reprogramming the genome of M13 bacteriophage for all-in-one personalized cancer vaccine
JP7561182B2 (ja) ペプチドがロードされたキャリアシステムおよびその使用
Shen et al. Vaccines developed for cancer immunotherapy
Xie et al. An mRNA Tumor Nanovaccine Expressing Tumor Antigen Fused With Angiotensin II Facilitates Type 1 Conventional Dendritic Cell‐Mediated Anti‐Tumor Immunity
HK40076004A (en) Core/shell structure platform for immunotherapy
FR2822707A1 (fr) Association d'un antigene tumoral et d'un systeme de delivrance d'une cytokine ou d'une chemokine a des fins d'immunotherapie du cancer
HK40015928A (en) Core/shell structure platform for immunotherapy